AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer

Clinical Trial ID NCT02298946

Rank	Title	Journal	Year	PubWeight™‹?›
1	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.	Nat Med	2007	13.90
2	Calreticulin exposure dictates the immunogenicity of cancer cell death.	Nat Med	2006	10.54
3	Immune parameters affecting the efficacy of chemotherapeutic regimens.	Nat Rev Clin Oncol	2011	3.41
4	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
5	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.	Oncoimmunology	2015	1.07
6	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.	World J Gastroenterol	2016	0.87
7	Novel therapeutic agents in the treatment of metastatic colorectal cancer.	World J Gastrointest Oncol	2016	0.83
8	Trial Watch: Immunotherapy plus radiation therapy for oncological indications.	Oncoimmunology	2016	0.81
9	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.	Ther Adv Med Oncol	2016	0.81
10	The emerging role of immunotherapy in colorectal cancer.	Ann Transl Med	2016	0.80
11	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.	J Immunol Res	2015	0.78